12月15日,生物医药公司诺诚健华宣布,其核心产品奥布替尼用于治疗系统性红斑狼疮(SLE)的IIb期临床研究达到主要终点,并已获国家药品监督管理局批准开展Ⅲ期临床试验。 这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步,但其通往成功商业化的道路仍布满不确定性,或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。 Ⅱ期到Ⅲ期存变数 资料显示,奥布替尼是一款布鲁顿...
Source Link12月15日,生物医药公司诺诚健华宣布,其核心产品奥布替尼用于治疗系统性红斑狼疮(SLE)的IIb期临床研究达到主要终点,并已获国家药品监督管理局批准开展Ⅲ期临床试验。 这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步,但其通往成功商业化的道路仍布满不确定性,或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。 Ⅱ期到Ⅲ期存变数 资料显示,奥布替尼是一款布鲁顿...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.